Compugen (NASDAQ:CGEN) Upgraded by StockNews.com to “Buy”

StockNews.com upgraded shares of Compugen (NASDAQ:CGEN) from a hold rating to a buy rating in a research report released on Thursday morning.

Separately, Truist Financial reduced their price objective on Compugen from $5.00 to $4.00 and set a buy rating for the company in a report on Tuesday, May 21st.

Compugen Price Performance

NASDAQ CGEN opened at $1.84 on Thursday. The business’s fifty day moving average is $1.80 and its 200-day moving average is $2.13. The stock has a market capitalization of $159.40 million, a price-to-earnings ratio of -9.68 and a beta of 2.60. Compugen has a one year low of $0.53 and a one year high of $3.03.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.06. The company had revenue of $6.70 million during the quarter, compared to the consensus estimate of $2.68 million. During the same period in the prior year, the firm posted ($0.11) EPS. Research analysts expect that Compugen will post 0.05 EPS for the current fiscal year.

Hedge Funds Weigh In On Compugen

Large investors have recently modified their holdings of the business. Heron Bay Capital Management bought a new position in shares of Compugen in the first quarter worth $32,000. Secure Asset Management LLC purchased a new stake in Compugen during the 2nd quarter worth about $69,000. Squarepoint Ops LLC lifted its holdings in Compugen by 23.4% during the 2nd quarter. Squarepoint Ops LLC now owns 85,693 shares of the biotechnology company’s stock worth $144,000 after purchasing an additional 16,253 shares in the last quarter. Rothschild Investment LLC bought a new position in Compugen in the 2nd quarter worth about $380,000. Finally, ARK Investment Management LLC grew its holdings in Compugen by 4.7% during the 2nd quarter. ARK Investment Management LLC now owns 1,088,271 shares of the biotechnology company’s stock valued at $1,850,000 after buying an additional 48,979 shares in the last quarter. Hedge funds and other institutional investors own 12.22% of the company’s stock.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.